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Myocardial infarction (MI) and ischemic heart disease are the 
leading causes of death in the industrial world. Coronary artery 
bypass grafting (CABG) and percutaneous coronary interven-
tions (PCIs) are the mainstays of treatment for these patients 
and significantly reduce morbidity and mortality (1). Unfortu-
nately, nearly 10% of all patients are ineligible for these proce-
dures for reasons including presence of diffuse or intractable 
lesions. Additionally, a substantial number of diabetic patients 
that undergo these procedures show insufficient improvement. 
Without treatment, many of these patients do poorly, with mor-
tality rates of 8%–10% per year (2).
Recently, a noninvasive approach aimed at promoting growth 
of new coronary blood vessels has been proposed to treat patients 
that are not eligible for CABG and PCI. This strategy, termed 
pharmacological angiogenesis, involves either systemic or local admin-
istration of proangiogenic agents, such as FGF or VEGF-A, into 
the heart. Despite promise in animal models, FGF and VEGF-A 
therapy has thus far shown little efficacy in clinical studies (2–5).
In search of new candidate pharmacological targets, we and oth-
ers have discovered that activation of hedgehog (HH) signaling in 
the adult heart is sufficient to promote coronary neovasculariza-
tion and protect from ischemia (6, 7). These studies directly impli-
cated the HH signaling pathway as a potential therapeutic target for 
pharmacological angiogenesis. Interestingly, through investigation 
of potential effects of HH activation, it was noted that HH ligands, 
most prominently sonic hedgehog (SHH), were expressed in the 
adult heart (6). Expression of SHH in the adult heart raised the pos-
sibility that endogenous HH signaling may be important for normal 
cardiac homeostasis or function. Consistent with this, we have pre-
viously reported that HH signaling is essential for the formation of 
the coronary vascular system during embryonic development (7).
To determine whether HH signaling is required for adult cardiac 
homeostasis or function, we examined the consequences of acutely 
removing HH signaling from the adult mouse heart. We show that 
temporal and tissue-specific deletion of the essential HH signaling 
component smoothened (Smo) leads to reductions in proangio-
genic gene expression and dropout of coronary blood vessels. Loss 
of coronary vasculature resulted in tissue hypoxia, cardiomyocyte 
apoptosis, ventricular failure, and lethality. These data demon-
strate that HH signaling is required in the normal adult mouse 
heart to maintain proangiogenic gene expression and promote 
survival of the coronary vasculature.
Results
SHH and patched1 are expressed in the adult heart. To identify cell 
types that express SHH and potential targets of HH signaling, 
we examined expression of SHH and patched1 (PTC1) in the 
normal adult mouse heart. Consistent with previous studies, 
immunohistochemical analysis for β-galactosidase in Ptc1-LacZ 
knock-in hearts (8) revealed that PTC1 is expressed in cardiomyo-
cytes and perivascular smooth muscle (Figure 1, A–H). Since PTC1 
is both a receptor for and marker of HH signaling (9), these data 
suggest that cardiomyocytes and perivascular smooth muscle cells 
represent 2 potential targets of HH signaling.
Immunohistochemical examination for SHH protein demon-
strated that SHH was expressed in both the adventitial layer of 
larger blood vessels and in cells surrounding smaller blood ves-
sels located within the interstitium. Colabeling with Abs against 
the fibroblast marker vimentin revealed that SHH was specifically 
expressed in adventitial and perivascular interstitial fibroblasts 
(Figure 1, I–L). To gain further insight into the spatial relation-
ship among the coronary microvasculature, SHH-expressing cells, 
and PTC1-expressing cells, we performed immunohistochemical 
analysis with Abs against PECAM, SHH, and β-galactosidase in 
Ptc1-LacZ knock-in mice (Figure 1, M–P). Colabeling experiments 
revealed that SHH and PTC1 were expressed in interstitial cells 
and cardiomyocytes, respectively, in close association with the 
coronary microvasculature.
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Together, these data suggest that SHH likely signals to 2 inde-
pendent populations of cells, perivascular smooth muscle cells and 
cardiomyocytes. SHH expressed from adventitial fibroblasts may 
signal to surrounding perivascular smooth muscle cells, poten-
tially affecting larger coronary blood vessel growth or physiology. 
Additionally, SHH expressed from interstitial fibroblasts may 
control aspects of coronary microvascular growth or function via 
signaling to the cardiomyocyte.
Myocardial HH signaling is required 
for survival and cardiac function.  
To identify functions of HH signaling 
in the adult heart, we inactivated HH 
signaling in the 2 potential targets of 
SHH, the cardiomyocyte and vascu-
lar smooth muscle cell. Myocardium-
specific ablation of HH signaling in 
the adult heart was accomplished 
by conditionally removing a homo-
zygous floxed allele of Smo (10), an 
essential transducer of HH signaling, 
using α–myosin heavy chain–ER-Cre 
(αMHC-ER-Cre). The αMHC-ER-Cre 
(mer) transgenic mouse allows spa-
tiotemporal control of Cre recom-
binase activity in the cardiomyocyte 
(11). The αMHC promoter drives 
expression of an ER-Cre fusion pro-
tein in the myocardium, and upon 
administration of tamoxifen, the ER-
Cre protein is translocated into the 
nucleus, promoting Cre-mediated 
recombination (Figure 2A). Similar-
ly, the Sm22-Cre mouse was used to 
target vascular smooth muscle (Fig-
ure 2B). Injection of tamoxifen into 
adult Smomer mice resulted in deletion 
of Smo and ablation of HH signaling 
in the adult myocardium. Targeting 
Smo with Sm22-Cre (Smosm22) resulted 
in constitutive ablation of Smo in vas-
cular smooth muscle cells. Mating 
Smomer and Smosm22 mice to generate 
Smomer,sm22 mice enabled deletion of 
Smo from both the cardiomyocyte 
and vascular smooth muscle cell lin-
eages concurrently.
To remove HH signaling from the adult 
heart, we injected control (Smoflox/flox), 
Smosm22, Smomer, and Smomer,sm22 mice 
with tamoxifen once per day for 5 con-
secutive days (Figure 2C). Treatment 
with 5 injections of tamoxifen pro-
motes Cre-mediated recombination 
in up to 90%–95% of cardiomyoctyes 
(11) (Figure 2A). Following the fifth 
injection (day 5), Smomer and Smomer,sm22 
mice became tachypneic, with ensuing 
lethality between days 3 and 7 (Figure 
2C). Smomer and Smomer,sm22 mice that 
were not injected with tamoxifen were 
indistinguishable from controls (data not shown). Similarly, mice 
of the genotype Smoflox1+;mer or Smoflox1+;mer,Sm22 that were injected 
with tamoxifen were also indistinguishable from control mice (data 
not shown). Unless specifically stated, all further comparisons were 
made between tamoxifen-injected animals.
Examination of control, Smosm22, Smomer, and Smomer,sm22 hearts 
revealed that by day 5, Smomer and Smomer,sm22 hearts displayed 
cardiomegaly and ventricular dilation (Figure 2, D–G). Consis-
Figure 1
SHH and PTC1 expression in the adult heart. (A–D) Immunohistochemical staining of Ptc1-LacZ 
adult hearts with Abs against cardiac actin (B, green) and β-galactosidase (C, red) demonstrating 
PTC1 expression in cardiomyocytes (white arrows) and large coronary vessels (white arrowheads). 
A shows the corresponding differential interference contrast (DIC) microscopy image. (E–H) 
Immunohistochemical staining of Ptc1-LacZ adult hearts with Abs against PECAM (E, blue), SMA 
(F, green), and β-galactosidase (G, red). PTC1 expression was detected in both cardiomyocytes 
and perivascular smooth muscle cells. White arrowheads denote colocalization of PTC1 and SMA 
expression. (I–L) Immunohistochemical staining with Abs against PECAM (I, blue), vimentin (J, 
green), and SHH (K, red) revealed that SHH is expressed in adventitial and interstitial fibroblasts. 
White arrowheads denote colocalization of SHH and vimentin expression. The asterisk indicates 
area of vimentin and PECAM coexpression. (M–P) Immunostaining with PECAM (M, blue), SHH 
(N, green), and β-galactosidase (O, red) demonstrates a close association among SHH-expressing 
interstitial fibroblasts, PTC1-expressing cardiomyocytes, and blood vessels (white arrowhead). In 
E–G, I–K, and M–O, florescent signals are overlaid on top of DIC images. D, H, L, and P show 
merged images of A–C, E–G, I–K, and M–O, respectively. Original magnification, ×400 (A–D, I–L, 
and M–P); ×200 (E–H).
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tent with cardiac damage and impaired cardiac function, Smomer 
and Smomer,sm22 mice demonstrated fibrotic replacement of myo-
cardial tissue (Figure 2, H–K). Moreover, echocardiographic 
analysis of fractional shortening in control, Smosm22, Smomer, and 
Smomer,sm22 mice at day 5 confirmed severely depressed systolic 
function in Smomer and Smomer,sm22 mice (Figure 2, L–P, Table 1, 
and Supplemental Video 1; available online with this article; 
doi:10.1172/JCI34561DS1). Serial echocardiography demon-
strated persistently diminished systolic function for at least 8 
weeks following tamoxifen injections in surviving Smomer and 
Smomer,sm22 mice (data not shown). Quantitative RT-PCR revealed 
elevated levels of Anp and Bnp compared with those in control 
and Smosm22 hearts (Figure 2Q).
Cardiomegaly, chamber dilation, impaired systolic function, 
and fibrotic replacement of myocardial tissue strongly suggest 
that lethality seen in Smomer and Smomer,sm22 mice is a result of heart 
failure. Consistent with this, Smomer and Smomer,sm22 mice became 
tachypneic and demonstrated histological evidence of pulmonary 
venous congestion and edema (data not shown). These data indi-
cate that cardiac HH signaling is essential for preservation of car-
diac function and that acute loss of myocardial HH signaling leads 
to heart failure and subsequent lethality.
Myocardial HH signaling is necessary for maintenance of the coro-
nary vasculature. Given the close proximity of SHH-expressing 
interstitial fibroblasts and PTC1-expressing cardiomyocytes to 
the coronary microvasculature and the severe cardiac dysfunc-
tion seen in injected Smomer and Smomer,sm22 mice, we hypothesized 
that myocardial HH signaling may preserve cardiac function by 
maintaining the coronary vasculature. To test this hypothesis, 
we examined the coronary vasculature of control, Smosm22, Smomer, 
and Smomer,sm22 hearts. PECAM staining after 5 days of tamoxifen 
injection revealed that Smomer and Smomer,sm22 hearts contained sig-
nificantly (P < 0.01) fewer numbers of blood vessels (75.3 and 64.1 
vessels/×100 field) compared with Smosm22 and control hearts (128 
and 137 vessels/×100 field) (Figure 3, A–D, and I). There was a 
small but statistically significant reduction in blood vessel num-
Figure 2
Myocardial HH signaling is required 
for survival and cardiac function. (A 
and B) β-Galactosidase staining of 
Rosa26Rmer (A) and Rosa26Rsm22 (B) 
hearts showing Cre-mediated recombi-
nation in cardiomyocytes and vascular 
smooth muscle cells, respectively. Orig-
inal magnification, ×200. (C) Kaplan-
Meier survival curve demonstrating 
lethality in Smomer and Smomer,sm22 
mice between days 5 and 7. The red 
bar denotes the 5-day tamoxifen injec-
tion period. (D–G) Whole-mount pho-
tographs of transverse heart slices at 
day 5, revealing that Smomer (F) and 
Smomer,sm22 (G) mice have enlarged and 
dilated ventricles compared with con-
trol (D) and Smosm22 (E) mice. Original 
magnification, ×25. (H–K) Trichrome 
staining demonstrating replacement 
of cardiomyocytes by fibrotic tissue in 
Smomer (J) and Smomer,sm22 (K) hearts. 
No fibrosis was seen in control (H) and 
Smosm22 (I) hearts. Original magnifica-
tion, ×200. (L–O) 2D M-mode images 
of control (L), Smosm22 (M), Smomer 
(N), and Smomer,sm22 (O) hearts, show-
ing impaired systolic function in Smomer 
and Smomer,sm22 hearts. (P) Quantitation 
of fractional shortening, demonstrat-
ing statistically significant reductions 
in Smomer and Smomer,sm22 mice com-
pared with control and Smosm22 mice. 
(Q) Quantitative RT-PCR revealed ele-
vated levels of Anp and Bnp in Smomer 
and Smomer,sm22 hearts compared with 
control and Smosm22 hearts. *P < 0.01.
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ber between Smomer,sm22 and Smomer hearts (P < 0.01). Labeling with 
SMA Abs demonstrated that Smomer hearts had increased num-
bers of smooth muscle–positive coronary vessels (27.9 vessels/×20 
field) compared with control, Smosm22, and Smomer,sm22 hearts (19.1, 
19.1, and 16.4 vessels/×20 field; P < 0.01) (Figure 3, E, F, G, H, 
and J). Smomer,sm22 hearts had a small but statistically significant 
decrease in smooth muscle cell–containing coronary vessels com-
pared with controls (P < 0.05).
These data indicate that HH signaling to the myocardium is 
specifically required for maintenance of smaller coronary ves-
sels. In the presence of myocardial HH signaling, HH signaling to 
vascular smooth muscle cells is not necessary for survival of the 
coronary vasculature. However, in the absence of myocardial HH 
signaling, there is an expansion in the number of smooth muscle–
containing coronary vessels that is dependent on HH signaling to 
perivascular smooth muscle cells.
To further characterize the type of blood vessels affected by loss 
of cardiac HH signaling, we bred arterial- and venous-specific 
Efnb2-LacZ and Ephb4-LacZ reporter mice (12, 13) into the Smo 
background. β-Galactosidase staining of Smomer,sm22;Efnb2-LacZ 
and Smomer,sm22;Ephb4-LacZ mice revealed that while arterial blood 
vessels were selectively affected by loss of myocardial HH signaling, 
venous blood vessels were spared (Figure 3, K–N).
Consistent with coronary vascular dropout, expression of the 
proangiogenic factors Vegfa, Vegfb, Vegfc, Ang1, and Ang2 were sig-
nificantly reduced in Smomer and Smomer,sm22 hearts compared with 
those of controls (Figure 3O). Expression of Vegfd and Ang3 was 
unaffected (data not shown). Ptc1 expression was similarly dimin-
ished in Smomer and Smomer,sm22 hearts, suggesting that the myocar-
dium is the target of the majority of HH signaling in the adult 
heart. Together, these data demonstrate that myocardial, and to 
a much lesser extent vascular smooth muscle, HH signaling is 
required for expression of Vegfa, Vegfb, Vegfc, Ang1, and Ang2 and 
for the maintenance of smaller arterial coronary blood vessels.
Removal of HH signaling from adult hearts results in cell death and 
tissue hypoxia. To investigate whether coronary vessel dropout 
in Smomer and Smomer,sm22 hearts results in cell death and/or tis-
sue hypoxia, we examined histological sections of day 5 control, 
Smosm22, Smomer, and Smomer,sm22 hearts. TUNEL staining revealed 
increased cell death in Smomer and Smomer,sm22 hearts compared 
with Smosm22 and control hearts (Figure 4, A–D). TUNEL staining 
was present in both cardiomyocytes and coronary endothelial 
cells, demonstrating that cardiomyocyte cell death and coro-
nary vessel dropout are due to apoptosis. To confirm these 
results, control, Smosm22, Smomer, and Smomer,sm22 hearts were sub-
jected to active caspase-3 staining. Similar to what was observed 
with TUNEL staining, Smomer and Smomer,sm22 hearts contained 
increased numbers of active caspase-3–positive cardiomyocytes 
and coronary endothelial cells compared with Smosm22 and con-
trol hearts (Figure 4, E–H).
Concurrent coronary blood vessel dropout and cardiomyocyte 
apoptosis are consistent with the possibility that tissue hypoxia 
may be the result of lost coronary vasculature and the cause of 
cardiomyocyte cell death. To determine whether this might be the 
case, control, Smosm22, Smomer, and Smomer,sm22 hearts were directly 
examined for evidence of tissue hypoxia. Hypoxia was detected 
using the hypoxyprobe-1 system (14), which identifies cells that are 
exposed to a pO2 of less than 10 mmHg. Hypoxyprobe-1 staining 
demonstrated substantial numbers of hypoxic cardiomyocytes in 
Smomer and Smomer,sm22 hearts, compared with an absence of hypoxic 
cells in control and Smosm22 hearts (Figure 4, I–L).
To further investigate whether ventricular failure and cardio-
myocyte cell death are a consequence of disrupting coronary 
vascular density in Smomer,sm22 hearts, we temporally defined the 
sequence by which these events occur. Cardiac dysfunction, as 
assessed by ventricular dilation, was first present by the fourth 
day of tamoxifen treatment (Figure 5, A–D). Beginning the third 
day of tamoxifen treatment, preceding the development of ven-
tricular dilation, a statistically significant reduction in coronary 
vessel density was evident compared with that in uninjected 
Smomer,sm22 hearts. Coronary vessel density sharply declined fol-
lowing the fourth and fifth day of tamoxifen treatment (Figure 
5, E–J). Tissue hypoxia was detected beginning on the fourth day 
of tamoxifen treatment, coinciding with the onset of ventricular 
dysfunction and significant loss of coronary vessel density (Fig-
ure 5, K–N). Cardiomyocyte cell death and fibrotic replacement 
of cardiac tissue were only detected following the fifth tamoxi-
fen injection (Figure 5, O–V). Together, these data indicate that 
coronary vascular disruption and subsequent tissue hypoxia, 
respectively, precede and coincide with the onset of ventricular 
dysfunction. Moreover, cardiomyocyte cell death and fibrosis 
occur only following these events, suggesting that loss of coro-
nary vessel density and resultant tissue hypoxia are responsible 
for ventricular dysfunction, cardiomyocyte apoptosis, and fibro-
sis in hearts deficient in HH signaling.
HH signaling is not necessary for survival of cardiomyocytes. To 
formally exclude the possibility that HH signaling to cardio-
myocytes is directly required for their survival, we investigated 
whether inhibition of HH signaling promotes neonatal mouse 
cardiomyocyte cell death in vitro. Treatment of mouse neona-
tal cardiomyocytes with cyclopamine did not result in increased 
cell death compared with vehicle control treatment. In contrast, 
hydrogen peroxide led to significant increases in cardiomyocyte 
cell death (Figure 6, A–D). To determine whether sufficient inhi-
Table 1
Echocardiographic parameters at day 5 of tamoxifen injection
Genotype	 LVIDd	 LVIDs	 LVPWs	 LVAWs	 LVPWd	 LVAWd	 %	FS	 RWT
Control 3.1 ± 0.2 1.0 ± 0.1 1.4 ± 0.2 1.6 ± 0.1 0.6 ± 0.07 0.6 ± 0.07 67 ± 2.4 0.38 ± 0.06
Smosm22 3.2 ± 0.1 1.1 ± 0.2 1.3 ± 0.1 1.6 ± 0.2 0.6 ± 0.02 0.7 ± 0.08 66 ± 4.6 0.44 ± 0.03
Smomer 4.1 ± 0.4A 2.7 ± 0.7A 1.0 ± 0.2A 1.2 ± 0.3A 0.6 ± 0.09 0.7 ± 0.11 33 ± 9.4A 0.32 ± 0.06
Smomer,sm22 4.3 ± 0.8A 3.5 ± 1.1A 0.8 ± 0.5A 1.0 ± 0.2A 0.6 ± 0.10 0.7 ± 0.07 22 ± 10A 0.34 ± 0.02A
LVIDd, LV internal dimension, diastolic; LVIDs, LV internal dimension, systolic; LVPWs, LV posterior wall thickness, systolic; LVAWs, LV anterior wall thick-
ness, systolic; LVPWd, LV posterior wall thickness, diastolic; LVAWd, LV anterior wall thickness, diastolic; % FS, percent fractional shortening; RWT, rela-
tive wall thickness. AP < 0.05 compared with control.
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Figure 3
Cardiac HH signaling is necessary for maintenance of the coronary vasculature. (A–H) Immunohistochemical staining of control (A and E), Smosm22 
(B and F), Smomer (C and G), and Smomer,sm22 (D and H) hearts with Abs against PECAM (A–D) and SMA (E–H), demonstrating alterations in blood 
vessel number and composition in Smomer and Smomer,sm22 hearts. PECAM staining reveals decreased numbers of total blood vessels in Smomer and 
Smomer,sm22 hearts compared with control and Smosm22 hearts. SMA staining shows increased numbers of smooth muscle–positive blood vessels in 
Smomer hearts, which is abolished in Smomer,sm22 hearts. The dashed lines demarcate the boundary of myocardial tissue. Original magnification, ×400 
(A–D); ×100 (E–H). (I) Quantitation of the total number of blood vessels/×100 field in control, Smosm22, Smomer, and Smomer,sm22 hearts, revealing a 
statistically significant reduction in Smomer and Smomer,sm22 hearts. Smomer,sm22 hearts have a further reduction in blood vessels compared with Smomer 
hearts. *P < 0.01 compared with control; **P < 0.01 compared with control and Smomer hearts. (J) Quantitation of smooth muscle cell–positive blood 
vessels, showing a statistically significant increase in the number of smooth muscle–positive blood vessels in Smomer hearts (*P < 0.01). Smomer,sm22 
hearts have a slight reduction in smooth muscle–containing blood vessels compared with controls (#P < 0.05). (K–N) β-Galactosidase staining for 
Efnb2-LacZ (artery marker) in control (K) and Smomer,sm22 (L) hearts, demonstrating a reduction in ephrinB2-positive cells in Smomer,sm22 hearts. 
β-Galactosidase staining for Ephb4-LacZ (vein marker) in control (M) and Smomer,sm22 (N) hearts, revealing that control and Smomer,sm22 hearts contain 
similar numbers of ephB4-positive cells. Original magnification, ×200. (O) Quantitative RT-PCR showing diminished Ptc1, Vegfa, Vegfb, Vegfc, Ang1, 
and Ang2 expression in Smomer and Smomer,sm22 hearts compared with control and Smosm22 hearts. *P < 0.01 compared with controls.
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bition of HH signaling was achieved, we measured the expres-
sion of 2 HH-responsive transcripts, Ptc1 and Vegfa. Consistent 
with inhibition of HH signaling, mRNA expression of both Ptc1 
and Vegfa was significantly diminished in response to cyclopa-
mine treatment (Figure 6E).
Endogenous HH signaling is critical for recovery from cardiac ischemia. 
Previous work has demonstrated that SHH expression is increased 
following cardiac ischemia (6). To determine whether endogenous 
HH activity is important for recovery from myocardial ischemia, 
neutralizing anti-mouse SHH Abs were administered to wild-type 
mice following MI. Briefly, wild-type mice underwent surgical liga-
tion of the left anterior descending artery (LAD) and were exam-
ined by high-resolution echocardiography the next day to measure 
baseline cardiac function and infarct size. Mice were subsequently 
randomized to receive either isotype control or neutralizing SHH 
Ab injections i.p. daily for 14 days. Following treatment, mice 
underwent a second echocardiographic assessment of cardiac 
function and infarct area.
An initial mortality was observed in both the control and SHH 
Ab–treated groups within 1 day following LAD ligation and is an 
expected outcome of this MI model.  However, several of the mice 
receiving the SHH Ab exhibited an additional mortality between 
days 4 and 7 (Figure 7A). Echocardiographic assessment of cardiac 
function on day 14 revealed a diminished ejection fraction in mice 
receiving the SHH Ab compared with controls (Figure 7, B and C), 
despite similar ejection fractions on day 1 after MI (Figure 7, D 
and E). Pairwise analysis revealed that mice treated with the SHH 
Ab underwent a significantly greater decline in ejection fraction 
compared with those in the control group (–18.6% versus –58.5%; 
P < 0.01) (Figure 7, D–F).
We also assessed the control and SHH Ab–treated groups for 
changes in infarct area by both histology and echocardiography 
(Figure 7, G–J). Compared with the control group, mice receiv-
ing the SHH Ab demonstrated a significant increase in infarct 
area. Despite a similar infarct size day 1 after MI, pairwise analy-
sis demonstrated an increase in infarct area in SHH Ab–treated 
mice compared with control Ab–treated mice (4.5% versus 31.2%; 
P < 0.01) (Figure 7, K–M).
Consistent with increased infarct area, SHH Ab–treated mice 
had a reduction in border zone coronary vessel density, as mea-
sured at either day 4 or day 14 following MI, compared with 
control mice (day 4, 126 versus 74 vessels/×100 field, and day 
14, 116 versus 81 vessels/×100 field; P < 0.01) (Figure 8, A–C). 
Importantly, SHH Ab–treated mice had significantly greater 
amounts of border zone tissue hypoxia and cell death 4 days 
after MI (Figure 8, D–G). Consistent with reduced HH signal-
ing, VEGF-A and PTC1 expression was reduced in the border 
zone of SHH Ab–treated mice compared with controls on day 4 
following MI (Figure 8, H–K). Together, these data indicate that 
endogenous HH signaling plays a critical role in the response to 
cardiac ischemia, both preserving cardiac function and minimiz-
ing infarct area, possibly by enhancing border zone vasculature 
and minimizing tissue hypoxia.
Discussion
Using spatiotemporal specific gene targeting, we have demonstrat-
ed that myocardial HH signaling is required for the maintenance 
of the coronary microvasculature. Acute ablation of HH signal-
ing in the adult mouse heart resulted in coronary vessel dropout, 
tissue hypoxia, cardiomyocyte apoptosis, heart failure, and lethal-
ity. Moreover, reduction of HH signaling following MI resulted in 
worsened cardiac function, decreased border zone vasculature, and 
increased infarct size. These data demonstrate that HH signaling 
is essential for maintenance of the coronary vascular system and 
heart function in both the normal and ischemic heart.
Coronary vessel dropout, tissue hypoxia, and cardiomyocyte 
cell death in Smomer and Smomer,sm22 hearts strongly suggest that 
myocardial cell death is due to ischemic injury. These data do 
not exclude the possibility that myocardial HH signaling may 
directly promote cardiomyocyte survival. Treatment of adult car-
diomyocytes with SHH protein in vitro can protect from hydro-
gen peroxide–induced cell death (6). However, the presence of 
Figure 4
Loss of cardiac HH signaling results in 
cell death and tissue hypoxia. (A–D) 
TUNEL staining revealed increased 
apoptosis in Smomer (C) and Smomer,sm22 
(D) hearts compared with control (A) 
and Smosm22 (B) hearts. TUNEL-posi-
tive cardiomyocytes (black arrows) 
and coronary endothelial cells (black 
arrowheads) were observed. (E–H) 
Immunostaining of control (E), Smosm22 
(F), Smomer (G), and Smomer,sm22 (H) 
hearts with Abs against active cas-
pase-3, demonstrating expression 
in cardiomyocytes (black arrows) 
and coronary endothelial cells (black 
arrowheads) in Smomer and Smomer,sm22 
hearts. (I–L) Hypoxyprobe-1 staining 
of control (I), Smosm22 (J), Smomer (K), 
and Smomer,sm22 (L) hearts showing 
hypoxic cardiomyocytes (black arrows) 
in Smomer and Smomer,sm22 hearts. Orig-
inal magnification, ×400.
Downloaded on August 16, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/34561
research article
2410	 The	Journal	of	Clinical	Investigation   http://www.jci.org   Volume 118   Number 7   July 2008
hypoxic myocardial tissue in Smomer and Smomer,sm22 mice indicates 
that the observed coronary vessel dropout is not only function-
ally significant but is likely the etiology of cardiomyocyte cell 
death and ventricular dysfunction.
HH signaling represents a conserved pathway essential for both the 
embryonic and the adult vasculature. Previously, we have reported 
that an HH/VEGF/angiopoietin pathway controls the forma-
tion of the coronary vascular system during development and 
that reactivation of HH signaling in the adult heart can promote 
coronary neovascularization (7). Here, we demonstrate that HH 
signaling is not only necessary for coronary vascular develop-
ment but is required for maintenance of the adult coronary vas-
culature primarily at the level of the microvasculature. Together, 
these findings indicate that both the embryonic and adult coro-
Figure 5
Coronary blood vessel loss and 
tissue hypoxia lead to cardiac fail-
ure and cardiomyocyte cell death 
in hearts deficient in HH signaling.  
(A–D) H&E-stained sections of 
Smomer,sm22 hearts prior to day 0 
(A) and after 3 (B), 4 (C), and 5 
(D) days of tamoxifen treatment, 
revealing ventricular dilation begin-
ning at day 4 of tamoxifen treat-
ment. Original magnification, ×25. 
(E–H) Immunofluorescence staining 
for PECAM, revealing decreased 
coronary vessel density beginning 
after 3 days of tamoxifen treat-
ment (F) compared with baseline 
(E). Coronary blood vessel density 
continues to decline after the fourth 
(G) and fifth (H) days of treatment. 
Original magnification, ×400. (I and 
J) Quantification of the number of 
blood vessels/×100 field (I) and 
the number of blood vessels/myo-
cyte (J), demonstrating continuous 
decline in vascular density at days 
3, 4, and 5 compared with baseline. 
*P < 0.01 compared with day 0; 
**P < 0.01 compared with day 3; 
***P < 0.01 compared with day 4. 
(K–N) Hypoxyprobe staining reveal-
ing the presence of hypoxic tissue 
after days 4 and 5 of tamoxifen 
treatment (black arrows). (O–R) 
TUNEL staining indicating that 
cardiomyocyte cell death occurs 
beginning after day 5 of tamoxifen 
treatment (black arrow). (S–V) Tri-
chrome staining demonstrating that 
fibrosis is first detected beginning on 
the fifth day of tamoxifen treatment 
(white arrow). Original magnifica-
tion, ×200. (W) Schematic depicting 
the sequence of events that occurs 
following tamoxifen treatment of 
Smomer,sm22 mice.
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nary vasculature are regulated by a conserved genetic pathway 
involving HH, VEGF, and angiopoietin signaling.
While there is great similarity between embryonic and adult 
coronary vascular growth, we have noticed some differences. In 
contrast to embryonic coronary vessel growth, where HH sig-
naling controls Ang2 expression, in the adult heart, HH signal-
ing regulates both Ang1 and Ang2 expression. Given that ANG1 
activates the TIE2 receptor and ANG2 antagonizes TIE2 recep-
tor activation (15), these data suggest that signaling through the 
TIE2 receptor is differentially required for embryonic coronary 
vascular growth and adult maintenance. Consistent with this, 
overexpression of Ang1 in the adult heart inhibits VEGF-induced 
coronary vessel growth, while overexpression of Ang2 enhances 
coronary vessel growth (16).
Myocardial HH signaling specifically regulates small coronary arterial 
vessels. Interestingly, deletion of Smo in the myocardium led to a 
specific decrease in the coronary arterial but not venous vascula-
ture, suggesting that coronary arteries and veins are supported 
through distinct mechanisms. Furthermore, hearts deficient in 
HH signaling preferentially demonstrated deficits in small vessels 
including the microvasculature. Whether coronary veins are main-
tained through a Vegf-dependent mechanism or another system is 
unclear. However, transgenic mice that specifically express Vegfa in 
the myocardium demonstrate selective increases in coronary arter-
ies but not veins, indicating that coronary veins might not be a 
target of VEGF signaling (16).
Determination of whether and which VEGF receptors are 
expressed in coronary endothelial cells will be necessary to ade-
quately address this question. It is possible that in addition to 
lymphatic vessels, coronary veins express VEGFR3. This would 
have interesting ramifications, suggesting potential coregulation 
of venous and lymphatic growth. Consistent with this, developing 
veins express VEGFR3 in zebrafish (17). Alternatively, coronary 
veins could be controlled via VEGF-independent mechanism(s).
Implications for disease and therapeutics. Given that Shh expression 
is induced following myocardial ischemia and that HH signaling 
is necessary and sufficient for coronary vascular growth, it seems 
likely that HH signaling constitutes an important mechanism to 
limit the extent of damage following myocardial ischemia and 
MI. This notion is supported by experiments demonstrating that 
reductions in HH signaling worsen cardiac function and increase 
infarct size following MI. These findings not only indicate that HH 
signaling plays a critical role following myocardial ischemia, but 
also suggest that endogenous HH activity may serve as a biomarker 
predictive of the extent of recovery after MI. That is, HH activity 
may reflect the potential to develop new coronary vasculature in 
borderline ischemic areas, limiting infarct expansion and further 
loss of cardiac function. Identification of patients with a low prob-
ability of expected recovery will undoubtedly improve the ability to 
optimally manage and select appropriate interventions after MI. 
Further studies are warranted to determine whether measurements 
of HH ligands or reporters of HH activity can be used in this way.
In addition to ischemic heart disease, our findings have impor-
tant implications for the use of HH antagonists. Currently, HH 
antagonists are being developed for the treatment of several can-
cers, including basal cell carcinoma, pancreatic carcinoma, pros-
tate carcinoma, chondroblastoma, and medulloblastoma (18–25). 
Given the profound effect of removing HH signaling from the 
myocardium, caution should be taken in the development of 
these pharmaceuticals. It is possible that therapeutic effects of 
HH antagonists may be achieved at levels of HH inhibition that 
do not impair cardiac function. The dose of the anti-SHH Ab that 
we administered resulted in no obvious change in cardiac function 
in control animals (data not shown). However, use of HH antago-
nists in patients with prior or ongoing cardiovascular disease may 
significantly increase the risk of further damage and should only 
proceed following careful investigation.
Methods
Tamoxifen treatment. All animal experiments were approved by the Wash-
ington University Animal Studies Committee. To inactivate HH signal-
ing in the myocardium, 3- to 4-month-old control (Smoflox/flox), Smosm22, 
Smomer, and Smomer,sm22 mice were injected i.p. with 0.1 mg/g tamoxifen 
(Sigma-Aldrich) once per day for 5 consecutive days. Tamoxifen was dis-
solved in sunflower oil (Sigma-Aldrich). All mice were backcrossed at 
least 3 generations onto the C57BL/6J background. The Rosa26R mouse 
(26) was used as a reporter for efficiency and localization of ER-Cre–
mediated gene recombination in the presence of tamoxifen.
Figure 6
HH signaling is not required for survival of 
mouse neonatal cardiomyocytes. (A–C) 
TUNEL staining of neonatal mouse cardio-
myocytes treated for 24 hours with vehicle 
(A), 10 μM cyclopamine (B), or 0.1% hydro-
gen peroxide (C). Original magnification, 
×200. (D) Quantification of TUNEL staining, 
demonstrating that only hydrogen peroxide 
treatment led to significantly increased cell 
death compared with vehicle control. cyclop, 
cyclopamine. (E) Quantitative RT-PCR dem-
onstrating that compared with vehicle control, 
cyclopamine treatment leads to reduced Ptc1 
and Vegfa expression. *P < 0.01.
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Histology. Tissues were fixed in 4% PFA overnight at 4°C, dehydrated in 
70% ethyl alcohol, and embedded in paraffin. Four-micrometer sections 
were cut and stained with either H&E or trichrome.
Immunohistochemistry and β-galactosidase staining. For colabeling experi-
ments, tissues were fixed in 2% PFA overnight at 4°C, embedded in OCT, 
infiltrated with sucrose, and frozen, and 10- to 12-μm cryosections 
were cut. Primary Abs used were: PECAM (R&D), 1:200; SMA (Sigma-
Aldrich), 1:400; LacZ (Abcam), 1:250; vimentin (Chemicon; Millipore), 
1:400; and SHH (5E1; Developmental Studies Hybridoma Bank), 1:100. 
The following secondary Abs were used at 1:200: anti-rat Alexa Fluor 
555, anti-rabbit Alexa Fluor 488, anti-rabbit Alexa Fluor 647, anti-goat 
Alexa Fluor 647, and anti-mouse Alexa Fluor 488 (Molecular Probes). 
Immunofluorescence was visualized on a Zeiss ApoTome Microscopy sys-
tem. Blood vessel number was quantified by examining at least 3 sections 
from 4 independent samples.
For caspase-3 staining, 4-μm paraffin sections were deparaffinized, 
rehydrated, peroxidase blocked, and antigen exposed by boiling in 10 mM 
citric acid. The primary Ab was anti–active caspase-3 Ab (Cell Signaling 
Technology Inc.), 1:200. The secondary Ab was biotinylated anti-rabbit 
(Vector Laboratories), 1:200. Signal was detected using the Elite ABC Kit 
(Vector Laboratories).
TUNEL staining was performed on paraffin-embedded sections as speci-
fied by the manufacturer (In Situ Cell Death Detection Kit; R&D Systems). 
LacZ staining was performed as described previously (26).
Figure 7
Endogenous HH signaling is critical for recovery following cardiac ischemia. (A) Kaplan-Meier survival curve showing the initial lethality following 
LAD ligation in both control and SHH Ab groups. However, between days 4 and 7 after MI, a fraction of the mice receiving SHH Ab died. The red 
arrow denotes the time at which mice underwent LAD ligation, and the red bar indicates the days mice received Ab injections. (B and C) Long-
axis end-systolic images of control (B) and SHH Ab–treated (C) hearts, demonstrating diminished ventricular function in SHH Ab–treated mice. 
Green arrows highlight the LV cavity. (D and E) Pairwise comparison of ejection fraction 1 day after MI (prior to Ab injections) and 14 days after 
MI (after Ab injections) in control (D) and SHH Ab–treated (E) mice. (F) Quantitation of the relative change in ejection fraction, demonstrating 
that SHH Ab–treated mice undergo a more severe decline in cardiac function compared with control mice (*P < 0.01). (G–J) Trichrome stain-
ing (G and H) and short-axis echocardiographic images (I and J) of control (G and I) and SHH Ab–treated (H and J) mice showing increased 
infarct size in SHH Ab–treated animals. Green arrows denote the infarct border zones. Original magnification, ×25 (G and H). (K and L) Pairwise 
comparison of infarct area 1 day after MI (prior to Ab injections) and 14 days after MI (after Ab injections) in control (K) and SHH Ab–treated (L) 
mice. (M) Quantitation of the relative change in infarct area (IA), demonstrating that SHH Ab–treated mice undergo an exaggerated increase in 
infarct area compared with control mice (*P < 0.01).
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Hypoxyprobe-1 staining. Mice were injected i.p. with 60 mg/kg hypoxyprobe-1 
(Chemicon; Millipore). Thirty minutes following injection, mice were sacri-
ficed, and hearts were dissected and fixed as specified for routine histological 
analysis. Four-micrometer paraffin-embedded sections were stained with the 
anti–hypoxyprobe-1 Ab as per the manufacturer’s instructions.
RNA isolation, cDNA synthesis, and quantitative RT-PCR. RNA was isolated 
from 4 independent biological samples using the RNeasy kit (QIAGEN). 
cDNA was obtained using the SuperScript II First-Strand cDNA Synthe-
sis kit (Invitrogen). Quantitative RT-PCR was performed on an ABI 7900 
machine using TaqMan probes for Vegfa, Vegfb, Vegfc, Vegfd, Ang1, Ang2, 
Ang3, and Hprt (ABI; Applied Biosystems). All samples were normalized 
to Hprt and then scaled relative to controls, where control samples were 
set at a value of 1. Thus, results for all experimental samples were graphed 
as relative expression compared with control. Error bars represent SD. 
P values were calculated using Student’s t test.
Neonatal cardiomyocyte isolation. Mouse neonatal cardiomyocytes were 
isolated and cultured using the Neonatal Cardiomyocyte Isolation System 
(Worthington Biochemical Corp.). Cells were plated overnight in serum-
containing medium and then switched to serum-free medium the follow-
ing morning. Cells were then treated with vehicle, 10 μM cyclopamine, 
or 0.1% hydrogen peroxide for 24 hours and then assayed for cell death 
(TUNEL), and RNA was harvested as described above.
Echocardiography. Mouse echocardiography was performed in the Wash-
ington University Mouse Cardiovascular Phenotyping Core facility using 
an ACUSON Sequoia Echocardiography System. High-resolution echocar-
diography (VisualSonics) was utilized for phenotypic analysis of cardiac 
function and infarct area for the MI studies (see below).
MI. Briefly, mice were randomized to receive either anti-mouse SHH Ab 
(5E1; Developmental Studies Hybridoma Bank) or isotype control (6B3; 
Developmental Studies Hybridoma Bank). Prior to Ab injection, mice 
underwent LAD ligation as previously described (27). On day 1 after MI, 
mice underwent echocardiography to access infarct area and ejection frac-
tion. Following this analysis, the mice were injected i.p. with either con-
trol or SHH Ab daily for 14 days. Mice received 10 mg/kg on days 1–3 and 
5 mg/kg thereafter. On day 14 after MI, mice underwent a second echocar-
diographic assessment and were then sacrificed. Ejection fraction was calcu-
lated by measuring the end systolic and diastolic dimensions from long-axis 
images. Infarct area was calculated by examining serial short-axis images 
(0.1 mm apart) spanning from the base of the heart (level of aortic valve) to 
the apex. The percent area of the ventricle that was infarcted was calculated 
by determining the percent of the ventricle that was akinetic. The percent 
change in ejection fraction or infarct area was calculated for each mouse. 
The average percent change was then calculated for the control and SHH Ab 
groups and compared using standard Student’s t test analysis.
Statistics. Data are expressed as mean ± SD. Student’s t test was used for 
comparisons between groups. P values of less than 0.05 were considered 
significant. P values of less than 0.01 are additionally identified in the text, 
figures, and figure legends.
Figure 8
Endogenous HH signaling is required for survival of the border zone vasculature. (A and B) PECAM staining of the border zone of control (A) and 
SHH Ab–treated (B) hearts 4 days after MI, demonstrating that SHH Ab–treated animals have diminished border zone vasculature compared 
with controls. Original magnification, ×100. (C) Quantitation of blood vessel number/×100 field reveals that compared with controls (Cont), SHH 
Ab–treated hearts contain a statistically significant decrease in the number of blood vessels located within the border zone at days 4 and 14 after 
MI (*P < 0.01). (D and E) Hypoxyprobe staining revealing increased hypoxic tissue in the border zone of SHH Ab–treated hearts (E) compared 
with controls (D). (F and G) TUNEL staining demonstrating that SHH Ab–treated hearts (G) have increased border zone cell death of cardiomyo-
cytes (arrows) compared with controls (F). (H–K) Immunofluorescence staining for VEGF-A (H and I) and β-galactosidase (J and K) in control 
(H and J) and SHH Ab–treated (I and K) PTC1-LacZ hearts, revealing that SHH Ab treatment leads to reduced VEGF-A and PTC1 border zone 
expression. Dashed lines indicate the border of the infarct. Original magnification: ×200 (D–G); ×400 (H–K).
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